Business Context and Reporting Period
This Form 8-K filing by Kura Oncology, Inc. (KURA) reports corporate governance changes effective August 9, 2019. The report was filed on August 12, 2019, and pertains to the departure of the former Chief Operating Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Departure: John Farnam ceased to be the Chief Operating Officer and an employee of the Company effective August 9, 2019.
- Appointment: Kathleen Ford was appointed as the new Chief Operating Officer effective August 9, 2019.
Management Commentary and Compensation Details
Ms. Ford's appointment includes an Executive Employment Agreement with the following terms:
- Base Salary: $400,000 annually.
- Target Bonus: 40% of base salary.
- Equity Grant: Option to purchase 250,000 shares of common stock at an exercise price of $19.45 per share (closing price on grant date), vesting monthly over four years.
- Severance Provisions:
- Termination without Cause or resignation for Good Reason: 12 months of base salary plus COBRA reimbursement for up to 12 months.
- Termination in connection with a Corporate Transaction: Full target bonus for the year plus accelerated vesting of 100% of outstanding unvested stock awards.
Investor Verification Checklist
- Verify the full text of the Executive Employment Agreement when filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2019.
- Confirm the vesting schedule and exercise price of the 250,000 stock options granted to Ms. Ford.
- Review the press release dated August 12, 2019, for additional context on the leadership transition.